Sprifermin is under clinical development by Formation Bio and currently in Phase II for Osteoarthritis. According to GlobalData, Phase II drugs for Osteoarthritis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Sprifermin LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sprifermin overview
Sprifermin (FGF 18) is under development for the treatment of knee osteoarthritis. The drug candidate is administered by intra-articular route. Sprifermin is a recombinant fibroblast growth factor-18 (FGF-18). It acts as an agonist of FGFR-3 and ERK 1/2. It is a new biological entity. It was also under development for cartilage injury of the knee.
Formation Bio overview
Formation Bio focuses on bringing treatments to patients faster by reimagining clinical trials. It accelerates the speed of clinical trials with the usability of advanced technologies, automation and data-driven solutions. The company focuses on creating a biopharma community in collaboration with researchers, patients, doctors and medical professionals. It helps doctors to retain their patients by providing new treatment options and broadening patient’s reach and accessibility. The company’s partners include Novartis, Pfizer, Sanofi and Aditum Bio. Formation Bio is headquartered in New York, the US.
For a complete picture of Sprifermin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
